Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AbCellera Biologics Inc.

< Previous 1 2 3 Next >
AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera and AbbVie Partner to Advance New Antibody Therapies
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Reports Q3 2022 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Present at Upcoming Investor Conferences in November
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Reports Q2 2022 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Reports Q1 2022 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Presents Data on T Cell Engager Platform at AACR 2022
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Reports Full Year 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Announces Changes to Its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Reports Q3 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Announces Virtual Presentations at Investor Conferences in November
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback